P21 (P021) P21
CNTF-derived peptide
Small CNTF-derived peptide (Ac-DGGLAG-NH2) studied for neurogenesis and synaptic plasticity effects in mouse models of Alzheimer's disease.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- CNTF-derived peptide
- Category
- Neuro, Cognitive & Sleep
- Type
- Single compound
- Abbreviation
- P21
- Development and regulatory status
- Not approved; preclinical research compound
What researchers study
Small peptide (Ac-DGGLAG-NH2) derived from ciliary neurotrophic factor (CNTF). Described as a neurotrophic peptide mimetic studied for effects on neurogenesis and synaptic plasticity in mouse models of Alzheimer's disease.
Research areas
- Neurogenesis and synaptic plasticity in mice
- Tau and amyloid pathology in transgenic Alzheimer's mice
- Spatial memory in rodent models
- Neurotrophic peptide mimetic design
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
Prenatal-to-early postnatal P021 treatment rescued cognitive deficits at 4 months and reduced tau hyperphosphorylation and plaque load at 22 months in 3xTg-AD mice
- rodent
It also improved postsynaptic markers PSD-95 and CREB activity and lowered the astrocyte marker GFAP
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- DihexaAnother memory and synaptic-plasticity peptide studied in rodent cognition models
- CerebrolysinNeurotrophic preparation with overlapping neurotrophin-pathway research focus
- AdamaxDescribed as incorporating P021-derived terminal modifications
